Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/28436
Title: Pharmacokinetic, tissue distribution, and excretion of puerarin and puerarin-phospholipid complex in rats
Authors: Li, Y
Pan, WS
Chen, SL
Xu, HX
Yang, DJ
Chan, ASC
Keywords: Excretion
HPLC
Phospholipid
Puerarin
Puerarin phospholipid complex
Serum kinetics
Tissue concentrations
Issue Date: 2006
Source: Drug development and industrial pharmacy, 2006, v. 32, no. 4, p. 413-422 How to cite?
Journal: Drug Development and Industrial Pharmacy 
Abstract: Puerarin is a potential therapeutic agent for cardiovascular diseases. But its poor oral bioavailability restricts its clinical application. In present study, as an evaluation of a formulation to improve the bioavailability of the drug, puerarin and its phospholipid complex were given to rats by intragastrically (i.g.) administration to compare pharmacokinetic, tissue distribution, and excretion. Serum samples were obtained at designated times after a single oral dose of 400 mg/kg puerarin or its complex. Tissue samples (heart, liver, spleen, kidney, lung, and brain), urine, and feces were collected and analyzed by a sensitive and specific high performance liquid chromatography (HPLC) method after i.g. administration of puerarin or its phospholipid complex. Compartmental and non-compartmental analyses were applied to the serum concentration versus time data. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. An open two-compartment, first-order model was selected for pharmacokinetic modeling. The results showed that after i.g. administration of 400 mg/kg puerarin and its phospholipid complex (equivalent to 400 mg/kg of puerarin), the pharmacokinetic parameters of the two formulations were different. The serum concentrations reached peaks at 0.894 ± 0.521 h and 0.435 ± 0.261 h, respectively, indicating the complex was more readily absorbed in serum than puerarin. The maximum concentrations for puerarin and its complex were 1.367 ± 0.586 mg·L-1 and 2.202 ± 1.28 mg·L-1 and AUC were 5.779 ± 1.662 mg·h L-1 and 8.456 ± 0.44 mg·h L-1, respectively, indicating a higher bioavailability for the complex. The widely distribution characteristics of puerarin and its complex in tissues post-i.g. administration was identical and in a descending order as follows: lung, kidney, liver, heart, spleen, and brain. However, the amount was different. Puerarin distribution was higher in heart, lung, and brain after administering the complex. The cumulative 72 h urinary excretion of puerarin after i.g. administration of puerarin and its complex accounted for 1.05%, 1.11% of the administered dose, respectively. The cumulative feces excretion of puerarin was 32.3% and 25.5%. To sum up, oral administration of puerarin phospholipid complex modified the pharmacokinetics and tissue distribution of puerarin and it could be an effective oral formulation for puerarin.
URI: http://hdl.handle.net/10397/28436
ISSN: 0363-9045
DOI: 10.1080/03639040600559123
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

37
Last Week
0
Last month
0
Citations as of Jun 16, 2017

WEB OF SCIENCETM
Citations

30
Last Week
0
Last month
0
Citations as of Jun 22, 2017

Page view(s)

31
Last Week
0
Last month
Checked on Jun 18, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.